REG - Alliance Pharma PLC - Share Options <ALAPH.L>
.
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100429:nRSc0672La
RNS Number : 0672L
Alliance Pharma PLC
29 April 2010
For immediate release 29 April 2010
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Share Options
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 29 April 2010 it awarded the
following options over ordinary shares of the Company to certain Directors.
Name Position Number of share options awarded Exercise price per share Date
of vesting Percentage of issued ordinary share capital
Tony Booley Director - Alliance Pharmaceuticals 116,500 34.25p 29
April 2013 0.05%
Peter Butterfield Director - Cambridge Laboratories 115,000 34.25p 29
April 2013 0.05%
Richard Wright Finance Director 118,650 34.25p 29
April 2013 0.05%
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney
Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge
Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the
treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's
disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies
with
their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
